Gantonoc, Gerve B.

HRN: 18-29-92  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/08/2024
CEFTRIAXONE 1G (VIAL)
08/08/2024
08/15/2024
IV
2g
Q25
Severe TBI Sec To MVA
Waiting Final Action 

Indication:  Prophylaxis    Type of Infection:  Skin & Soft TissueProphylaxis    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: